Pembrolizumab (pembro) for docetaxel-pretreated metastatic Castration-Resistant Prostate Cancer (mCRPC): Update on KEYNOTE-199, cohorts 1-3

Authors :: Charles Schloss
Ulka N. Vaishampayan
Jang Seop Kim
Marine Gross-Goupil
Ken-ichi Tabata
Josep M. Piulats
Tuomo Alanko
Susan Feyerabend
Raanan Berger
Emmanuel S. Antonarakis
R. de Wit
J.S. de Bono
Heshui Wu
Jeffrey C. Goh
Satoshi Fukasawa
Source :: European Urology Open Science, Vol 19, Iss, Pp e877-e878 (2020)
Publication Year :: 2020
Publisher :: Elsevier, 2020.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Urology
Pembrolizumab
Castration resistant
medicine.disease
lcsh:Diseases of the genitourinary system. Urology
lcsh:RC870-923
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
lcsh:RC254-282
Prostate cancer
Docetaxel
Internal medicine
medicine
business
medicine.drug

Tools